University of Cincinnati Cancer Center's efforts are leading to significant developments in the fight against blood cancers. Researchers at their Leukemia and Drug Development Lab (LDDL) are working tirelessly, analyzing patient samples to identify new mutations and collaborating with pharmaceutical companies to develop, test new therapeutic molecules, and pushing these potential treatments through Phase 1 clinical trials. The goal is to transform how blood cancers are treated and managed.
Despite the advancements in cancer treatment over the years, acute myeloid leukemia (AML) lags behind with a stagnant five-year survival rate of around 30%. Other types of cancer, like breast cancer, have seen survival rates increase significantly, thanks in part to dedicated research funding and precision medicine. The investment and focus that improved outcomes for breast cancer patients are what the work at the LDDL aims to replicate for blood cancers.
According to an article from UC's newsroom, Megan Johnstone, PhD, a member of the Cancer Center, compared blood cancers to an array of sprinkles, noting the diversity of mutations leading to treatment resistance. "So for example, AML is very heterogeneous," Johnstone explained. "You can think of your sprinkles container having 10 colors. You’re going to have 10 different types of AML, each with its own mutations and potential for treatment resistance."
The team is focusing on finding new ways to treat blood cancers when first-line drugs fail, a reality that occurs for many patients. The diversity of blood cancers means that when patients either develop resistance or experience a recurrence, they need personalized treatment options. Johnstone highlighted this challenge, “If you develop resistance, then it becomes a matter of new treatment options,” as per UC News, signaling not just a research opportunity but a necessary evolution in cancer care. While the work is ongoing, the dedication of UC's researchers mirrors the urgent need for innovation in this critical area of medicine, aiming to make living with blood cancer a possibility for many more patients in the years to come.
